Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase 2
Terminated
NCT03425331
| Condition | Non-small Cell Lung Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Terminated |
|---|
| Enrollment | 5 participants |
|---|
| Interventions | Ipilimumab, Nivolumab |
|---|
| Start date | Apr 10, 2018 |
|---|
| Completion date | May 18, 2020 |
|---|
| Results posted | Aug 22, 2024 |
|---|
Summary
This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: * Ipilimumab * Nivolumab
Best Response
Disease was evaluated radiologically at baseline and then every 6 weeks for the first 6 cycles of therapy. Median treatment duration for this study cohort is 8.05 months with range (2.76 months - 15.90 months). · Participants
| Nivolumab+Ipilimumab | 3 Participants |
|---|
| Nivolumab+Ipilimumab | 2 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.